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270 (IQR 96-457) at 2 years. In controls (n = 45) the values
were 367 (230-475) at baseline and 345 (IQR 245-455) at 2
vears. The difference in median levels at 2 years was statisti-
callv sianificant (P = 0.03).
5. The difference in fibre intake shown in Table 2 is not statisti-
cally significant. However. in the trial as a whole. when the
difference in fibre intake is the same but the number of
subjects is ofcourse much larger. the difference between inter-
vention and control groups is highly sianificant.
We thus find no evidence to support the suggestion that a higher
proportion of the intervention group was entering menopause at
baseline. However. it does seem that the main effect ofthe dietary
intervention on oestradiol levels may be in women over 45 years.
although this conclusion is based on small numbers and is obvi-
ouslv preliminary.
NBovd
Div-ision ofEpidemiology and Statistics. Ontario Cancer Institute,
Princess Margaret Hospital. Toronto. Ontario. Canada
Basal cell carcinoma of the face: surgery or
radiotherapy? Results of a randomized study
Sir,
I read with interest the recent paper by Avril et al ( 1997
describing the results of a prospective study comparing surgery
and radiotherapy in the management of basal cell carcinomas
(BCCs) of the face in 347 patients. Because both tumour recur-
rence rates and cosmesis were found to be significantly better in
the surgically managed group. the authors concluded that surgery
should be considered as the first-line treatment ofchoice for facial
BCCs less than 4 cm in diameter.
While there is undoubtedly a need for good randomized
prospective trials comparing the effectiveness ofthe two treatment
options. this study did not address the issues of management as
they are commonly encountered in current clinical practice. In the
study. the authors compared the treatment modalities in patients
with a wide range of clinical presentations. The size of tumours.
for example. ranged from 3-5 mm (10%c) to 31-40 mm (0.9%c) in
diameter. with 57%7c of tumours < 10 mm and 93%c <20 mm. Most
lesions were non-ulcerated nodules clinically. with a smaller
number of superficial (22%c) and morphoeic-type BCCs (4%7c). The
affected sites included the forehead. cheeks. chin. ears and nose.
It is perhaps these broad inclusion criteria that weakened the
overall value ofthe trial. One ofthe fundamental principles ofskin
cancer management is. wxhen possible. to completely remove
tumours (Flemingy et al. 1995). In practice. most dermatologists
would opt for excision of lesions if it were both technically
possible and likely to give good cosmetic results. As the majority
of BCCs in both treatment groups were < 1 cm in diameter. it
seems likelT that many of these tumours would have been
amenable to simple surgical excision with primary closure. In
those cases treated with radiotherapy. surgical intervention would
not only have avoided multiple outpatient visits. or even lengthy
inpatient stays. but would have permitted histological assessment
ofresection margins.
In their conclusions. the authors stated that. for facial BCCs less
than 4 cm in diameter. surgery is the treatment ofchoice. It is well
recognized that radiotherapy has a valuable role in the manage-
ment of particular clinical problems. such as tumours affectinc,
cartilaginous areas and the treatment of large ulcerated lesions
often encountered in elderly patients (Fleming et al. 1995). This
conclusion. while undoubtedly true for small lesions amenable to
excision. disregards the usefulness of radiotherapy in the manage-
ment oflarger and more awkwardly situated lesions.
Dr Susan Holmes
Department ofDermatologY,
University ofGlasgowz
REFERENCES
Avl MF. Aupenn A. Mareulis A et al 1997 Basal cell carcinoma of the face:
suraer'- orradiotherapy? Results of a randomized studs. BrJ Cancer 76:
100-106
Fleming ID. Amonette R. Monaghan T and Fleming MD 1995! Principles of
management of basal and squamous cell carcinoma of the skin Cancer 75:
699-704
Expression of bcJl2 protein in follicular lymphomas:
a report from a south Indian hospital
Sir,
The t 14:18) translocation juxtaposes part of the immunoglobulin
heavy-chain gene on chromosome 14 with the bcl-2 gene on chro-
mosome 18. This translocation was discovered in most follicular-
centre cell lymphoma. The prevalance of t( 1418) shows a
geographical predilection. being highest in the USA and lowest in
Japan (Isaacson. 1991 ). The bcl-2 oncoprotein can be easily local-
ized using immunohistochemical staining. and this has been
studied in follicular lymphomas occumrng in the West. We
assessed the frequency of bcl-2 expression in follicular
lymphomas in 51 subjects from the Indian subcontinent.
Out of a total of 406 cases of non-Hodgkin's lymphoma diag-
nosed from 1 March 1995 to 30 September 1997. 55 were follic-
ular l-mphoma (1 3.5%). Formalin-fixed paraffin-embedded tissue
samples for immunohistochemistrv w-ere available in only 51 of
these cases. Immunohistochemical analysis was performed on
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